Peritoneal Immune System in Patients with Advance Epithelial Ovarian Cancer

REFERENCES

• Gandawidjaja L, Hau T. Anatomic, physiologic, bacteriologic and immunologic aspects of peritonitis. Acta Chir Belg 1997;97:163–167.
   Google Scholar
• Chechlinska M, Kaminska J, Markowska J, Steffen J. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residua/recurrent diseaseexamination. Int J Biol Markers 2007;22:172–180.
   PubMed Web of Science ®Google Scholar
• Ho HN, Wu MY, Yang YS, Peritoneal cellular immunity and endometriosis. Am J Reprod Immunol 1997;38:400–412.
   PubMed Web of Science ®Google Scholar
• Gerber SA, Rybalko, VY, Bigelow CE, Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006;169:1739–1752.
   PubMed Web of Science ®Google Scholar
• Ionodes CG, Platsoucas CD, Rashed S, Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257–4265.
   Google Scholar
• Melichar B, Freedman RS. Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer 2002;12:3–17.
   PubMed Web of Science ®Google Scholar
• Krist LF, Eestermans IL, Steenbergen JJ, Cellular composition of milky spots in the human greater omentum: An immunochemical and ultrastructural study. Anat Rec 1995;241:163–174.
   PubMedGoogle Scholar
• Sorensen EW, Gerber SA, Sedlacek AL, Omental immune aggregates and tumor metastatis within the peritoneal cavity. Immunol Res 2009;45:185–194.
   PubMed Web of Science ®Google Scholar
• Beelen RH. The greater omentum: Physiology and immunological concepts. Neth J Surg 1991;43:145–149.
   Google Scholar
• Kearney JF, Bartels J, Hamilton AM, Development and function of the early B cell reperoire. Int Rev Immunol 1992;8:247–257.
   PubMedGoogle Scholar
• Gabrilovich DI, Bronte V, Chen SH, The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425, author reply 426.
   Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–949.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141–1149.
   PubMed Web of Science ®Google Scholar
• Melichar B, Touskova M, Tosner J, Kopecky O. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie 2001;24:156–160.
   Google Scholar
• Wertel I, Polak G, Bednarek W, Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom 2008;74:251–258.
   Google Scholar
• Zou W, Machelon V, Coulomb-L'Hermin A, Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339– 1346.
   PubMed Web of Science ®Google Scholar
• Bamias A, Tsiatas ML, Kafantari E, Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 2007;106:75–81.
   PubMed Web of Science ®Google Scholar
• Dong HP, Elstrand MB, Holth A, NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125:451–458.
   PubMed Web of Science ®Google Scholar
• Santin AD, Hermonat PL, Ravaggi A, Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001;51:254–261.
   PubMed Web of Science ®Google Scholar
• Li X, Ye DF, Xie X, Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005;23:399–403.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zou L, Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-12 in the tumor microenvironment. J Immuno 2007;178:6730–6733.
   PubMed Web of Science ®Google Scholar
• Miyahara Y, Odunsi K, Chen W, Generation and regulation of human CD4+ IL-17 producing T cells in ovarian cancer. PNAS 2008;105:15505–15510.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860–867.
   PubMed Web of Science ®Google Scholar
• Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143–154.
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271–296.
   PubMed Web of Science ®Google Scholar
• Avigan D. Dendritic cells: Development, function and potential use for cancer immunotherapy. Blood Rev 1999;13:51–64.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767–811.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Patterson S, English N, Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999;29:2769–2778.
   PubMed Web of Science ®Google Scholar
• Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219–1226.
   PubMed Web of Science ®Google Scholar
• Dzionek A, Fuchs A, Schmidt P, BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037–6046.
   PubMed Web of Science ®Google Scholar
• O'Doherty U, Peng M, Gezelter S, Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487–493.
   PubMed Web of Science ®Google Scholar
• Betjes MGH, Tuk CW, Struijk DG, Antigen-presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis. Clin Exp Immunol 1993;94:377–384.
   Google Scholar
• Betjes MGH, Haks MC, Tuck CW, Beelen RH. Monoclonal antibody EBM11 (anti-CD68) discriminates between dendritic cells and macrophages after short-term culture. Immunobiol 1991;183:79–87.
   PubMedGoogle Scholar
• Kubicka U, Olszewski WL, Tarnowski W, Normal human immune peritoneal cells: subpopulations and functional characteristics. Scand J Immunol 1996;44:157–163.
   PubMed Web of Science ®Google Scholar
• Eisenthal A, Polyvkin N, Bramante-Schreiber L, Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 2001;32:803–807.
   PubMed Web of Science ®Google Scholar
• Melichar B, Savary C, Kudelka AP, Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998;4:799–809.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Cheng P, Mottram P, Dendritic cells subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64:5535–5538.
   PubMed Web of Science ®Google Scholar
• Sowter HM, Corps AN, Evans AL, Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997;77:607–614.
   PubMed Web of Science ®Google Scholar
• Paley PJ, Staskus KA, Gebhard K, Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98–106.
   PubMed Web of Science ®Google Scholar
• Santin AD, Hermonat PL, Ravaggi A, Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999;20:177–181.
   PubMed Web of Science ®Google Scholar
• Berger S, Siegert A, Denkert C, Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother 2001;50:328–333.
   Google Scholar
• Zhou J, Ye F, Chen H, The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 2007;35:290–300.
   PubMed Web of Science ®Google Scholar
• Rabinovich A, Medina L, Piura B, Huleihel M. Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 2010;21:122–128.
   PubMed Web of Science ®Google Scholar
• Berchuck A, Rodriguez G, Olt G, Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 1992;166:676–684.
   PubMed Web of Science ®Google Scholar
• Toutirais O, Chartier P, Dubois D, Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003;14:246–255.
   PubMed Web of Science ®Google Scholar
• Burger RA, Grosen EA, Ioli GR, Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res 1995;15:255–260.
   Web of Science ®Google Scholar
• Offner FA, Obrist P, Stadlmann S, IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995;7:542–547.
   PubMedGoogle Scholar
• Bennaceur K, Chapman JA, Touraine J, Portoukalian J. Immunosuppressive networks in the tumor environment and their effect in dendritic cells. Biochem et Biophysica Acta 2009;1795:16–24.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Schuler G, Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213–1222.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233–238.
   PubMed Web of Science ®Google Scholar
• Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001;2:1010–1017.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Iyoda K, Tarbell K, Direct expansion of functional CD25+ CD4+regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235–247.
   PubMed Web of Science ®Google Scholar
• Verhasselt V, Vosters O, Beuneu C, Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells. Eur J Immunol 2004;34:762–772.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562–567.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467–477.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360–3365.
   PubMed Web of Science ®Google Scholar
• Matsui T, Connolly JE, Michnevitz M, CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009;182:6815–6823.
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275–306.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells: Understanding immunogenicity. Eur J Immunol 2007;37:53–60.
   PubMed Web of Science ®Google Scholar
• Hadeiba H, Sato T, Habtezion A, CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 2008;9:1253–1260.
   PubMed Web of Science ®Google Scholar
• Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010;40:2667–2676.
   PubMed Web of Science ®Google Scholar
• Gilliet M, Liu YJ. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 2002;63:1149–1155.
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Zou L, Plasmacytoid dendritic cells induce CD8 +regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020–5026.
   PubMed Web of Science ®Google Scholar
• Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174:244–251.
   PubMed Web of Science ®Google Scholar
• Melichar B, Savary CA, Patenia R, Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003;13:435–443.
   PubMedGoogle Scholar
• Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res 2006;12:1515–1524.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–78.
   PubMed Web of Science ®Google Scholar
• Hibbs Jr., JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987;235:473–476.
   PubMed Web of Science ®Google Scholar
• Dong Z, Yoneda J, Kumar R, Fidler IJ. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J Exp Med 1998;188:755–763.
   PubMed Web of Science ®Google Scholar
• Loercher AE, Nash MA, Kavanagh JJ, Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999;163:6251–6260.
   PubMed Web of Science ®Google Scholar
• Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 19987;47:100–105.
   Google Scholar
• Kryczek I, Zou L, Rodriguez P, B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203;871–888.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zhu G, Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67:8900–8905.
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LFAG, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gyn Oncol 2010;117:366–372.
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V, Phenotypic and functional features of human Th17 cells. J Exp Med 2007;20:1849–1861.
   Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros, D, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203–213.
   PubMed Web of Science ®Google Scholar
• Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101–116.
   PubMed Web of Science ®Google Scholar
• Rabinowich H, Suminami Y, Reichert TE, Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276–284.
   PubMed Web of Science ®Google Scholar
• Lockhart DC, Chan Ak, Mak S, Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001;129:749–756.
   PubMedGoogle Scholar
• Tomsová M, Melichar B, Sedláková I, Steiner I. Prognostic significance of CD3+tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415–420.
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Castiglione F, Degl'Innocenti DR, Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16;590–596.
   Google Scholar
• Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci 2005;102:18538–18543.
   PubMed Web of Science ®Google Scholar
• Barnett B, Kryczek I, Cheng P, Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am J Reprod Immunol 2005;54:369–377.
   PubMed Web of Science ®Google Scholar
• Weaver CT, Harrington LE, Mangan PR, Th17 an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677–688.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 2006;18:349–356.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121–1133.
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, T helper lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28:29–39.
   PubMed Web of Science ®Google Scholar
• Egwuagu CE. STAT3 in CD4+ T helper cells differentiation and inflammatory diseases. Cytokine 2009;47:149–156.
   PubMed Web of Science ®Google Scholar
• Chen Q., Yang W., Gupta S., IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity.2008;29:899– 911.
   PubMedGoogle Scholar
• Wilson NJ, Boniface K, Chan JR, Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950–957.
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J, Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:942–949.
   PubMed Web of Science ®Google Scholar
• Kato IT, Furumoto H, Ogura T, Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001;282:735–738.
   PubMed Web of Science ®Google Scholar
• Leveque L, Deknuydt F, Bioley G, Interleukin-2 mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J Immunother 2009;32:101–108.
   Google Scholar
• Numasaki M, Fukushi J, Ono M, Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101;2620–2627.
   Google Scholar
• Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467–476.
   PubMed Web of Science ®Google Scholar
• Charles KA, Kulbe H, Soper R, The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011–3023.
   PubMed Web of Science ®Google Scholar
• Benchetrit F, Ciree A, Vives V, Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114–2121.
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766–4772.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253–257.
   PubMed Web of Science ®Google Scholar
• Curiel JT. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167–1174.
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H, The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11,8326–8331.
   PubMed Web of Science ®Google Scholar
• Leffers N, Gooden MJM, deJong RA, Prognostic significance of tumor-infiltrating T-lymphocytes in primary and matastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58:449–459.
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biol 2006;16:53–65.
   PubMed Web of Science ®Google Scholar
• Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791–5802.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Bossche J. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233–4244.
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Buckanovich RJ, Benencia F, Vascular leukocytes contribute to tumor vascularization. Blood 2005;105:679–681.
   PubMed Web of Science ®Google Scholar
• Balint K, Conejo-Garcia JR, Buckanovich R, Coukos G. Role of vascular leukocytes in ovarian cancer neovascularisation. Adv Exp Med Biol 2008;622:273–280.
   Google Scholar
• Coucos G., J.R. Conejo-Garcia JR, Buckanovich R., Benencia F. Vascular leukocytes: A population with angiogenic and immunosuppressive properties highly represented in ovarian cancer. Adv Exp Med Biol 2007;590:185–193.
   Google Scholar
• Bak SP, Walters JJ, akeya M., Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 2007;67:4783–4789.
   PubMed Web of Science ®Google Scholar
• Peter S, Bak G, Hart K, Berwin B. Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion. Translational Oncol.2009;2:291–299.
   Google Scholar
• Nishizuka Y., Sakakura T., Taguchi O., Mechanism of ovarian tumorigenesis in miceafter neonatal thymectomy in mice. Science 1969;166:753–755.
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Zou L, Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells. Discov Med 2005;5:489–492.
   Google Scholar
• Tringler B, Liu W, Corral L, B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44–52.
   Google Scholar
• Zang X, Sullivan PS, Soslow RA, Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010;23:1104–1112.
   PubMed Web of Science ®Google Scholar
• Simon I, Zhuo S, Corral L, B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006;66:1570–1575.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther 2009;9:677–688.
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Wilson JL, Milliken D, Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res 2001;61:4961–4965.
   PubMed Web of Science ®Google Scholar
• Jiang YP, Wu XH, Shi B, Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006;103:226–323.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263–274.
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Shibata K, Terauchi M, Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91–99.
   PubMed Web of Science ®Google Scholar
• Okamoto A, Nikaido T, Ochiai K, Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030–6039.
   PubMed Web of Science ®Google Scholar
• Takao M, Okamoto A, Nikaido T, Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17:1333–1339.
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Lee JR, Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867–1870.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Lange A, Mottram P, CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005;65:465–472.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Keller E, Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292:C987–C995.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–1103.
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Takahashi A, Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007;56:761–770.
   PubMed Web of Science ®Google Scholar
• Dworak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–4380.
   Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963–2970.
   PubMed Web of Science ®Google Scholar
• Byrne AT, Ross L, Holash J, Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721–5728.
   PubMed Web of Science ®Google Scholar
• Hu L, Hofmann J, Holash J, Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966–6971.
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Haisley C, Hurteau J, Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001;80:245–253.
   PubMed Web of Science ®Google Scholar
• Li X, Ye F, Chen H, Human ovarian carcinoma cells generate CD4+CD25+ regulatory T cells from peripheral CD4+CD25- T cells through secreting TGF-β. Cancer Letters 2007;253:144–153.
   Google Scholar
• Pepper MS. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997;8:21–43.
   PubMedGoogle Scholar
• Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180–191.
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Benencia F, Courreges MC, Tumor-infiltraiting dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004;10:950–958.
   PubMed Web of Science ®Google Scholar
• Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68:7684–7691.
   PubMed Web of Science ®Google Scholar
• Jarnicki AG, Conroy H, Brereton C, Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797–3806.
   PubMed Web of Science ®Google Scholar
• Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med 2010;9:62–70.
   PubMedGoogle Scholar
• Liu B, Nash J, Runowicz C, Ovarian cancer immunotherapy: Opportunities, progresses and challenges. J Hematol Oncol 2010;3:7–11.
   PubMedGoogle Scholar
• Kershaw MH, Westwood JA, Parker LL, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106–6115.
   PubMed Web of Science ®Google Scholar
• Barber A, Zhang T, DeMars LR, Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67:5003–5008.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360–3365.
   PubMed Web of Science ®Google Scholar